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Abstract 
Objectives: This analysis aims to determine 1) which methods of contraception are used by 
women in Malawi; 2) whether the methods differ by self-reported HIV status; and 3) whether 
frequency of condom use at last sex differs by self-reported HIV status. 
Methods: The analysis is based on 13,618 non-pregnant women aged 15-49 in the 2010 Malawi 
Demographic and Health Survey who had sexual debut and reported the result of their last HIV 
test. We accounted for the 2-stage cluster sampling design by applying cluster, stratum, and 
sample weights. Current contraceptive method analysis was restricted to the subgroup with 
contraceptive need (i.e., fecund women who did not want a pregnancy in next 12 months). 
Differences in use between HIV-positive and HIV-negative women were assessed with chi-
squared tests of significance.  
Results: The proportion reporting condom use at last sex was statistically significantly higher in 
HIV-positive women (34.5%, standard error (s.e.)=2.2) than HIV-negative women (8.5%, 
s.e.=2.2, p<.01). Among women with contraceptive need (N=12,658; 93.1%), use of long-acting 
reversible contraception (LARC) was low and did not differ between HIV-positive (1.4%, 
s.e.=0.44) and HIV-negative women (1.9%, s.e.=0.19, p=0.35). HIV-negative women (30.4%, 
s.e.=0.64) were more likely than HIV-positive women (15.6%, s.e.=1.4, p<.01) to use progestin-
only injections. Utilization of female sterilization was higher in HIV-positive women (17.9%, 
s.e.=1.8) than in HIV-negative women (9.2%, s.e.=0.38, p<.01).  
Conclusions: LARC use was low among women in Malawi. Female sterilization was higher 
than in many other countries in sub-Saharan Africa. Targeted interventions to promote 
contraception are urgently needed to prevent mother-to-child transmission of HIV in Malawi. 
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Introduction 
 Women who are infected with HIV risk transmitting the virus to their children when 
pregnant or breastfeeding. The World Health Organization (WHO) and the United Nations (UN) 
recommend a four-pronged approach to prevent mother-to-child transmission (MTCT) of HIV, 
consisting of 1) primary prevention of HIV infection, 2) preventing unintended pregnancies 
among HIV-infected women, 3) preventing HIV transmission from HIV-infected women to their 
fetuses during pregnancy and to their neonates after delivery, and 4) providing HIV care for 
HIV-infected mothers and their infants.
1
 Unfortunately, preventative mother-to-child 
transmission (PMTCT) programs are often designed to address only the third aspect of the 
approach by promoting the use of antiretroviral (ARV) prophylaxis to women who are pregnant 
or breastfeeding.
1
 
 In sub-Saharan Africa, a region that produces 90% of the 800,000 incident cases of 
children with HIV each year, MTCT is responsible for a portion of the HIV disease burden.
2
 
ARV prophylactic interventions require access to consistent prenatal and delivery care and 
breastfeeding alternatives, which may be unachievable for women in this region.
2
 Additionally, 
these interventions cannot benefit women who are HIV-positive but unaware of their status. 
Success of an ARV regimen depends on a series of progressive steps (Figure). Each part of the 
intervention has the potential for failure. 
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Figure 1: Series of events required for a pregnant woman to successfully receive full ARV 
prophylaxis (Stringer et al., 2008) 
 The second prong of the WHO/UN approach aims to prevent unintended pregnancies in 
HIV-positive women. Proper use of contraception to prevent unintended pregnancies can prevent 
vertical transmission of HIV.
3
 With use of highly effective contraception, an HIV-positive 
woman can prevent unintended pregnancy for as long as she desires. This may be for the rest of 
her life, or until the timing is appropriate for her to access other PMTCT services. Additionally, 
the use of contraception as a means of preventing MTCT is more cost effective than the use of 
other PMTCT services. When compared with the cost of other PMTCT services in President’s 
Emergency Plan for AIDS Relief countries, the yearly minimum cost savings of using family 
planning interventions (including the cost of outreach visits, methods, and services) to prevent 
undesired HIV-positive births versus using other PMTCT interventions (including the cost of 
training clinicians, HIV testing and counseling, and completed nevirapine doses for infants and 
mothers) ranged from $26,000 in Vietnam to $2.2 million in South Africa. The current 
prevalence of contraception use has prevented nearly 175,000 unplanned births to HIV-positive 
mothers in sub-Saharan Africa alone.
3
 
  Malawi is a landlocked country in sub-Saharan Africa bordered by Mozambique, 
Tanzania, and Zambia.
4
 Its total fertility rate (TFR) is the eighth highest globally at 5.6 children 
per woman, and adult prevalence of HIV is 10.04%.
4
 Malawi accounts for 4% of the HIV burden 
in sub-Saharan Africa.
5
 Though rigorous efforts have reduced HIV prevalence in recent years, 
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46,000 people still acquire HIV annually in Malawi.
6
 Malawi’s high HIV prevalence and 
incidence, combined with its high TFR, have the potential to result in a high prevalence of 
MTCT if not combatted with appropriate interventions. Estimates of contraception use in Malawi 
can be used as the first step in designing MTCT interventions that prevent unintended 
pregnancies in HIV-positive women. This study aims to determine which methods of 
contraception are used by women in Malawi and whether the methods differ by self-reported 
HIV status using data from the 2010 Malawi Demographic and Health Survey (MDHS). I 
describe all methods of contraception, but focus specifically on the use of long-acting reversible 
contraception (LARC), progestin-only injections, and female sterilization. These methods are 
highly effective for contraception and have the potential to prevent unintended pregnancies in 
HIV-positive women if used properly. Progestin-only injections are the most popular method of 
contraception in Malawi,
7
 with injectable depot medroxyprogesterone acetate (DMPA) being the 
most widely used type. This method requires a subdermal injection every three months. Female 
sterilization is also a frequently utilized method of contraception in Malawi.
7
 Female sterilization 
is useful to women who want to limit childbearing, as it is a highly effective, irreversible method 
of contraception involving removal, cutting, sealing, or tying fallopian tubes.  
 In addition to current method of contraception use, I aim to measure frequency of 
condom use at last sex, and determine whether the frequencies differ by self-reported HIV status. 
Condoms are the only barrier contraceptive method that can be used to prevent horizontal disease 
transmission. The 2010 MDHS provides a variable separate from the variable describing current 
contraceptive use that measures whether a woman used a condom the last time she had sexual 
intercourse. This is a better indicator of condom use than simply asking a woman if she uses 
condoms as her current method of contraception because she may be using another form of 
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contraception to prevent pregnancy, while simultaneously using condoms to prevent disease 
transmission.  
Literature Review 
 When used perfectly, most modern contraceptive methods are effective against 
unintended pregnancies. However, patterns of typical use often differ greatly from perfect use. 
LARC methods include intrauterine devices (IUD) and subdermal implants.
8
 These methods 
require a one-time insertion by a healthcare provider and are effective at preventing pregnancy 
for 3 to 10 years, depending on the specific device.
8
 “Typical” use of contraception describes the 
average effectiveness of a contraceptive method for a person who uses it inconsistently or 
incorrectly.
9
 “Perfect” use of contraception shows how effective a method is when directions for 
use are followed exactly. For most methods of contraception, failure rates of typical use and 
perfect use differ. However, LARCs are not user-dependent, and unintended pregnancy rates 
during the first year of use when used perfectly and when used typically are identical (0.2% for 
IUDs, 0.05% for subdermal implants).
9
 Therefore, LARC methods have the most potential of all 
reversible methods of contraception to prevent unintended pregnancies, including in HIV-
positive women. 
 Few studies have focused on the prevalence of LARC use in Malawi, but many have 
shown that LARCs are underutilized in other sub-Saharan African countries.
10
 The reasons 
behind this underutilization in Africa vary. Some medical providers may believe that IUDs are 
associated with immorality or cause infertility or disease, including pelvic inflammatory 
disease.
10
 Additionally, the emergency contraceptive capabilities of the copper IUD have 
convinced some clinicians that the IUD functions as an abortifacient. Physiological barriers may 
also prevent widespread IUD utilization because some providers will insert them in a patient 
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only during or directly after menstruation in order to be certain that a woman is not pregnant.
 
 
Additionally, some clinicians mistakenly
11
 believe that IUDs are not appropriate for use in 
nulliparous women. Provider training on IUD placement may be limited in some settings.
10
 
Finally, acceptor barriers to IUD utilization often relate to the fear of experiencing pain and 
discomfort during insertion and afterward, especially in nulliparous women. 
 Nationally representative surveys of clinicians conducted in South Africa and Zimbabwe 
showed that only 18% of clinical providers offered any type of IUD, and just 16% provided 
subdermal implants.
12 
Healthcare providers had overly restrictive ideas of which patients were 
eligible for LARC use, with just 5% and 15% saying that IUDs and implants (respectively) were 
appropriate for use in HIV-positive women or women at risk for HIV. Despite this, 82% of 
clinicians surveyed suggested that patients were not utilizing IUDs enough and ≥ 50% wanted 
more training regarding LARC use.  
 Another barrier to LARC uptake in Malawi may relate to the cost of the devices. Many 
women in Malawi access family planning services through mobile outreach services, because 
81% of the population lives in rural areas were access to health clinics is often impossible.
13
 
While short-acting contraceptive methods are supplied for free by the Family Planning 
Association of Malawi in mobile outreach settings, LARC methods usually come with a price. 
However, in these settings, the cost of LARCs are determined with a sliding scale, and most 
women are able to purchase a LARC for 40-50% less than the cost at a traditional clinic.  
 Regardless of these setbacks inhibiting LARC utilization, interest, desire, and eligibility 
to begin using LARCs is high among HIV-positive women in Malawi.
14
 A clinical trial 
conducted in Malawi’s capital, Lilongwe, found that of 281 HIV-positive women using ART, 
97.2% and 98.2% were eligible for IUD or implant insertion, respectively. After educational 
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information, when asked about their preference of contraceptive method, 34.9% of the women 
selected an IUD as their preferred method of contraception when asked to choose between 
combined hormonal contraceptives, progestin-only pills, DMPA, implants, and copper IUDs. 
However, when women were asked in a separate question if they would be willing to have an 
IUD inserted on the day of their visit, 79.0% agreed. Of the 21% who declined IUD insertion at 
that time, 37.3% said that they would like to have one in the future. These results suggest that 
LARC acceptability may be high among women who are HIV-positive in Malawi, and 
promoting it as a means of MTCT prevention may be worthwhile. Many barriers to LARC 
utilization appear to be effectively mitigated with proper education of both providers and 
patients.
14
  
 This analysis uses self-reported HIV status, as opposed to laboratory-confirmed HIV test 
results, to measure HIV status. Of all DHS data, self-reported HIV status is a variable assessed in 
only the 2010 Malawi and the 2011 Uganda AIDS indicator survey. HIV testing of respondents 
is standard procedure in Malawi, and the laboratory HIV test results of those who consented are 
available in a separate dataset. If HIV status is a predictor of contraceptive use, it is only relevant 
to use the status that women believe themselves to be, as opposed to the laboratory results, which 
they may not be aware of. 
Methods 
I. Participants 
 Data from the 2010 MDHS were used to conduct all analyses. The DHSs are nationally 
representative, cross-sectional household surveys conducted regularly in select low- and middle-
income countries under the direction of the Joint United Nations Programme on HIV/AIDS. Data 
from the 2010 MDHS was gathered by the National Statistical Office and the Ministry of Health 
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Community Services Unit.
15
 The 2010 MDHS used a two-stage cluster sampling design to select 
respondents. Malawi consists of 28 administrative districts, and the 2008 Malawi Population and 
Housing Census was first used to divide these districts into 849 clusters. There were 158 clusters 
in urban areas and 691 in rural areas. The distribution of clusters among the 28 districts was not 
determined by proportionality to the national population, because areas with low populations 
would not be comprised of enough clusters for adequate representation. Therefore, districts with 
low populations were oversampled. The second stage of sampling was based upon households. 
To provide an accurate depiction of survey indicators, at least 950 households were sampled per 
district. Overall, 25,311 households were selected and eligible for participation in the 2010 
MDHS.  
 The 2010 MDHS data are gathered in Woman’s, Man’s, and Household questionnaires.15 
The present analysis used data only from the Woman’s MDHS questionnaire. Respondents were 
interviewed about various topics using scripted questionnaires. A total of 24,825 households 
were successfully sampled, yielding a 98% response. MDHS staff identified 23,748 women aged 
15-49 as being eligible for inclusion, and 97% were successfully interviewed. A total of 23,020 
women’s responses were recorded in the 2010 MDHS. The present study limited its analysis 
population to women who were not pregnant, had ever had sexual intercourse, and reported the 
result of their last HIV test. Women who were pregnant or had never had sexual intercourse were 
excluded because they were not considered to be possibly using contraception as a means of 
MTCT prevention.  
II. Measures  
 The objectives of this study were to 1) identify the current methods of contraception used 
by women in Malawi; 2) determine whether the methods varied by self-reported HIV status; and 
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3) determine whether condom use at last sex varied by self-reported HIV status. HIV status was 
determined by each respondent’s answer to “Could you please tell me what was the result of 
your last test for the AIDS virus?” To determine if the frequency of condom use at last time of 
sexual intercourse varied by HIV status, responses were dichotomized based on each woman’s 
response to “Did you use a condom the last time you had sexual intercourse?” Response 
categories included yes or no. Note that condom use at last sex is a separate variable from current 
method of contraception use, so the analysis population for these two variables differs because 
they answer different questions. The analysis population used for describing the current method 
of contraception was limited to women who had a need for contraception. I created a derived 
dichotomous variable for contraceptive need. Women were considered to have contraceptive 
need if they were fecund and did not want a pregnancy in the next twelve months. A woman was 
considered fecund if she was not classified as “declared infecund” in response to the question 
assessing desire for more children. 
 Women using contraception at the time of survey indicated their current method from the 
following list: female sterilization, male sterilization, oral contraceptive pill, intrauterine device 
(IUD), progestin-only injectables, subdermal implants, male condoms, female condoms, periodic 
abstinence/rhythm, withdrawal, or other folk method. If a respondent reported using multiple 
methods, the highest ranked method was recorded (methods are listed in descending order). 
 Four derived, dichotomous variables were created to further analyze contraceptive 
methods used by women who had contraceptive need. The first variable described whether a 
respondent was using a modern contraceptive method. Modern methods of contraception, 
according to the World Health Organization, include female sterilization, male sterilization, the 
pill, IUD, injectables, implants, male condoms, and female condoms.
16
 The 2010 MDHS 
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provides a derived variable that categorizes current method used as no method, folkloric, 
traditional, or modern. The no method, folkloric, and traditional categories were combined, 
leaving the previously mentioned modern methods to define the “yes” category and rhythm, 
withdrawal, other folk methods, and use of no method as the “no” response. In addition to 
modern contraceptive method use, three dichotomous variables were created to describe whether 
or not a respondent was currently using each of the following methods: 1) LARCs; 2) progestin-
only injections; or 3) female sterilization.  
III. Analysis 
 SAS (Statistical Analysis System; version 9.4; SAS Institute; Cary, NC), was used for all 
analyses. Because the MDHS used a complex, 2-stage cluster sampling design, the present 
analysis used survey, strata, and cluster weights to adjust for the differences in probability of 
selection.  I used chi-squared tests of significance to test for differences by self-reported HIV 
status among all variables.  
 I used logistic regression to determine, in separate analyses, whether the following 
differed by HIV status: 1) progestin-only injection use; 2) female sterilization use; 2) condom 
use at last sex.  The latter two analyses were limited to women with contraceptive need. Odds 
ratios were not calculated for LARC use because of insufficient data—only a very small 
percentage of women were using a LARC method overall and within HIV-positive and HIV-
negative groupings. The analyses were adjusted for the following confounders: age, wealth 
quintile, type of place of residence (urban/rural), gravidity, and union status based on previous 
literature. I report adjusted odds ratios (aORs) with 95% confidence intervals (CIs) for 
differences by HIV status for the three outcomes of interest. 
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Results 
 Of the 23,020 women sampled in the 2010 MDHS, exclusions were applied to limit the 
analysis population (Figure 2). Women who had not reached sexual debut were excluded, 
leaving 19,880 women. Following this, pregnant women were excluded, resulting in 17,718 
women. Finally, those who had not reported the result of their last HIV test were excluded, 
resulting in a total of 13,618 women to comprise the final analysis population. Responses of 
“undetermined” or “refused to answer” to the HIV test result question were combined, producing 
a negligible 1.37%. These responses were set to missing data, and a dichotomous variable 
containing “positive” and “negative” responses was created.  
 
Figure 2: Exclusions applied to analysis population 
This analysis population was used to analyze all demographic variables. After further excluding 
women who did not have contraceptive need at the time of survey, 12,658 women remained, and 
this number served as the analysis population for contraceptive variables. 
DHS sample 
size: 23,020 
Sexually 
debuted: 
19,880 
Not 
pregnant: 
17,718 
Reported 
result of last 
HIV test: 
13,618 
N=13,618 
Luster 13 
 
 Among the analysis population of 13,618 women (Table 1), the mean age of respondents 
was 30 years and most lived in a rural area (80.1%, s.e.=0.92). About two-thirds (68.4%, 
s.e.=0.69) were married, with 5.6% (s.e.=0.28) reporting never having been married, and 25.7% 
(s.e.=0.63) living with partner, not living with partner, widowed, or divorced. Most women were 
Christian (86.1%, s.e.=0.76), followed by Muslim (13.0%, s.e.=0.76), and 0.8% (s.e.=0.13) 
reporting no religion. The median number of children ever born was four. Most women reported 
that their husband was residing in their home (86.3%, s.e.=0.54) and 60.2% (s.e.=0.73) said they 
were currently working. A total of 987 (7.2%, s.e.=0.33) of respondents reported being HIV-
positive. 
 Of the 13,618 women in the overall analysis population (not restricted by contraceptive 
need), the proportion of women who reported using a condom use at last sex was statistically 
significantly higher among HIV-positive women (34.5%, s.e.=2.2) than HIV-negative women 
(8.5%, s.e.=2.2, p<.01). Despite this, overall condom use at last sex was low, with only 10.0% 
(s.e.=0.41) of women reporting having used a condom the last time they had sexual intercourse.  
 
Table 1. Demographic characteristics of sexually debuted, non-pregnant women in Malawi, 2010 
       Self-Reported HIV Status 
 Total 
 (N=13,618) 
HIV Positive 
(N=987) 
HIV Negative 
(N=12,631) 
P-value 
 Unweighted 
No. 
Weighted 
(%) 
Unweighted 
No. 
Weighted 
(%) 
Unweighted 
No. 
Weighted 
(%) 
 
Age        
15-25 4,842 (36.5) 101 (10,1) 4,741 (38.5) <.01 
26-32 4,053 (30.1) 280 (29.3) 3,773 (30.1)  
33-49 4,723 (33.5) 606 (60.5) 4,117 (31.4)  
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Wealth Quintile 
Poorest 2,620 (17.8) 188 (17.1) 2,432 (17.9) 0.02 
Poorer 2,653 (18.4) 176 (15.8) 2,477 (18.6)  
Middle 2,789 (19.5) 180 (16.8) 2,609 (19.7)  
Richer 2,832 (20.2) 227 (24.0) 2,605 (19.9)  
Richest 2,724 (24.1) 216 (26.3) 2,508 (23.9)  
 
Region 
       
Northern  2,564 (12.1) 99 (6.7) 2,465 (12.4) <.01 
Central 4,328 (40.6) 198 (27.3) 4,130 (41.7)  
Southern 6,726 (47.3) 690 (66.0) 6,036 (45.9)  
        
 
Type of residence 
       
Urban 1,909 (19.9) 195 (25.4) 1,714 (19.5) <.01 
Rural 11,709 (80.1) 792 (74.6) 10,917 (80.6)  
        
Highest education         
None 2,073 (15.4) 194 (20.0) 1,879 (15.0) <.01 
Primary 8,934 (63.6) 644 (63.4) 8,290 (63.6)  
Secondary or 
more 
2,611 (21.0) 149 (16.6) 2,462 (21.3)  
        
Union status        
Never married 797 (5.6) 10 (1.1) 787 (6.2) <.01 
Married 9,308 (68.4) 475 (49.1) 8,833 (69.9)  
Living 
together, 
widowed, 
divorced, not 
living together 
 
3,513 (25.7) 502 (49.7) 3,011 (23.9)  
Religion        
Christian 12,006 (86.1) 882 (86.4) 11,124 (86.1) 0.93 
Muslim 1,501 (13.0) 97 (12.9) 1,404 (13.0)  
None 83 (0.8) 8 (0.7) 75 (0.8)  
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1 
Women considered to have contraceptive need included fecund women who reported not wanting birth within the 
next 12 months. 
 
 Women with contraceptive need (Table 2) composed the majority of the sample 
(n=12,658, 93.1%, s.e.=0.30). Among these women, 47.8% (s.e.=0.68) were using a modern 
method of contraception. The proportions of HIV-positive (48.1%, s.e.=2.3) and HIV-negative 
(47.8%, s.e.=0.69) women using modern methods were not statistically significantly different 
Number of 
children ever born 
0 4,562 (5.5) 32 (3.3) 698 (5.6) <.01 
Less than 4, 
more than 0 
8,326 (62.9) 546 (56.8) 7,780 (63.4)  
4 or more 730 (31.7) 409 (39.9) 4,153 (31.0)  
        
Husband lives in 
home  
       
Yes 9,117 (86.3) 455 (84.7) 8,662 (86.4) 0.40 
No 1,467 (13.7) 80 (15.3) 1,387 (13.6)  
 
 
Currently 
working 
       
Yes 8,360 (60.2) 673 (65.1) 7,687 (59.9) 0.02 
No 5,234 (39.8) 312 (34.9) 4,922 (40.1)  
        
Used condom at 
last sex 
       
Yes 1,174 (10.0) 234 (34.5) 940 (8.5) <.01 
No 10,399 (90.0) 439 (65.5) 9,960 (91.5)  
        
Need for 
Contraception
1
 
       
Yes 12,658 (93.1) 893 (90.0) 11,765 (93.3) <.01 
No 938 (6.9) 91 (10.0) 847 (6.7)  
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(p=0.90). The total proportion of women using a LARC method was 1.9% (s.e.=0.18), with 
similar proportions of HIV-positive (1.4%, s.e.=0.44) and HIV-negative (1.9%, s.e.=0.19, 
p=0.35) women using this method of contraception. Progestin-only injection use was high 
among women with contraceptive need, at 29.4% (s.e.=0.61).  HIV-negative women (30.4%, 
s.e.=0.64) were more likely than HIV-positive women (15.6%, s.e.=1.4) to use progestin-only 
injections (p<.01). In this sample, 9.8% (s.e.=0.39) women reported female sterilization as their 
current method of contraception. Use of this method was higher among HIV-positive women 
(17.9%, s.e.=1.8) than among HIV-negative women (9.2%, s.e.=0.38, p<.01). 
Table 2. Contraception use among sexually debuted, non-pregnant women with contraceptive need in 
Malawi, 2010 
       Self-reported HIV status 
 Total 
 (N=12,658) 
HIV Positive 
(N=893) 
HIV Negative 
(N=11,765) 
P-value 
 
 
Unweighted 
No. 
Weighted 
(%) 
Unweighted 
No. 
Weighted 
(%) 
Unweighted 
No. 
Weighted 
(%) 
 
All types
1
        
Not Using 6106 (48.4) 462 (50.4) 5644 (48.2) <.01 
Female 
Sterilization 
1240 (9.8) 154 (17.9) 1086 (9.2)  
Male 
Sterilization 
7 (0.1) 1 (0.0) 6 (0.1)  
Oral 
Contraceptive 
Pill 
334 (2.7) 11 (1.3) 323 (2.8)  
Intrauterine 
Device 
25 (0.3) 1 (0.3) 23 (0.3)  
Progestin-only 
Injection 
3655 (29.4) 135 (15.6) 3520 (30.4)  
Dermal 
Implant 
252 (1.6) 16 (1.1) 236 (1.6)  
Male Condom 500 (3.9) 90 (11.2) 410 (3.4)  
Female 
Condom 
14 (0.1) 6 (0.6) 8 (0.1)  
Periodic 
Abstinence 
96 (0.9) 2 (0.1) 94 (1.0)  
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1
If more than one method was reported, the highest method in the list was recorded 
2
Modern methods of contraception include pill, IUD, injections, diaphragm, condom, female sterilization, male 
sterilization, implants, female condom, foam/jelly, and lactational amenorrhea 
3
Long-acting reversible methods of contraception include intrauterine devices and dermal implants 
  
 Prevalence of condom use at last sex, female sterilization, and progestin-only injection 
use were statistically significantly different by HIV status. Among the analysis population 
unrestricted by contraceptive need, the adjusted odds (Table 3) of having used a condom at last 
sex were higher among HIV-positive women compared to HIV-negative women (aOR=7.1, 95% 
CI, 5.6-9.0). Among the 12,658 women with contraceptive need, the adjusted odds of being 
sterilized were higher among HIV-positive women than among HIV-negative women (aOR=1.5, 
95% CI, 1.1-2.1). In this same population, among HIV-positive women, the adjusted odds of 
Withdrawal 279 (1.8) 9 (1.0) 236 (1.6)  
Other 150 (1.2) 6 (0.4) 144 (1.2)  
 
 
 
Modern method
2
 
       
Yes 6027 (47.8) 414 (48.1) 5613 (47.8) 0.90 
No 6631 (52.2) 479 (51.9) 6152 (52.2)  
        
 
LARC method
3
 
       
Yes 277 (1.9) 17 (1.4) 260 (1.9) 0.35 
No 12381 (98.1) 876 (98.6) 11505 (98.1)  
 
 
 
Progestin-only 
injection method 
       
Yes 3655 (29.4) 135 (15.6) 3520 (30.4) <.01 
No 9003 (70.6) 758 (84.4) 8245 (69.6)  
 
Female 
sterilization 
       
Yes 1240 (9.8) 154 (17.9) 1086 (9.2) <.01 
No 11418 (90.2) 739 (82.1) 10679 (90.8)  
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using progestin-only injections were 0.6 times the odds of HIV-negative women (95% CI, 0.5-
0.7). 
Table 3. Association between types of contraception and self-reported HIV status 
 Progestin-only injection Female sterilization Condom use at last sex 
 aOR* (95% CI) aOR (95% CI) aOR (95% CI) 
Self-reported HIV status       
HIV-negative 1.0 - 1.0 - 1.0 - 
HIV-positive 0.6 (0.5-0.7) 1.5 (1.1-2.1) 7.1 (5.6-9.0) 
*Adjusted odds ratio, adjusting for age, wealth quintile, urban/rural residence, gravidity, and union status 
Discussion 
 According to nationally representative data collected in 2010 in Malawi, about half of 
women with in Malawi contraceptive need were using a modern method of contraception. 
Proportions of modern method use did not vary by self-reported HIV status. Few women with 
contraceptive need used LARC methods, with no difference in use by self-reported HIV status. 
HIV-positive women were more likely to be sterilized and less likely to be using progestin-only 
injections than their HIV-negative counterparts.  Among all respondents (regardless of 
contraceptive need), those who reported being HIV-positive were more likely to have used a 
condom the last time they had sex than those who were HIV-negative. While the odds of using a 
condom at last sex were higher among HIV-positive women compared with those who were 
HIV-negative, overall condom use was low. HIV-positive women who are not using condoms 
and LARC methods of contraception may be at higher risk for both horizontal and vertical 
transmission of the virus.  
 Female sterilization utilization was high in the sample, which is consistent with existing 
estimates of contraception in Malawi.
7
 The prevalence of female sterilization in Malawi is much 
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higher than in the rest of Africa, at about 10%, compared with 2%, respectively.
7 
Sterilization 
prevalence is so low in Africa as a whole due to a range of resource restraints, including lack of a 
substantial workforce of healthcare providers, poverty, and competing healthcare demands.
17
 
Like other countries in Africa, Malawi also faces these issues, but the prevalence of female 
sterilization remains high. This is because of public health programming efforts, which have 
increased demand for both female sterilization and desire to limit childbearing. Additionally, an 
enabling environment, public-private agreements, and availability of free mobile outreach 
services have also contributed to the rise in female sterilization utilization. The present analysis 
showed that HIV-positive women were much more likely to have been sterilized than HIV-
negative women, even after adjusting for multiple factors. To my knowledge, other studies have 
not determined whether this method of use varied by self-reported status in Malawi.  
 Limited data is available describing use of the specific contraceptive methods in this 
analysis by HIV status among women in Malawi or sub-Saharan Africa. Our analysis found that 
HIV-positive women are more likely to report using condoms than HIV-negative women, which 
is consistent with another DHS analysis conducted with data from Zambia (2007), Swaziland 
(2006-2007), and Zimbabwe (2005-2006).
18
 The same study found that similar proportions of 
HIV-negative and HIV-positive women were using modern methods of contraception, which is 
consistent with our findings. However, the mentioned study did not analyze more specific 
methods of use aside from this.  
 
Research suggests that women who use DMPA injectables could be at a higher risk for 
acquiring HIV than their counterparts who use oral contraceptives containing estrogen and 
progestin or norethisterone enanthate (NET-EN), another form of injectable contraception.
19
 
Prior MDHS analysis in women aged 15-24 showed that progestin-only injection users had 
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higher, though non-significant, HIV seroprevalence than non-users.
20
 This may be because the 
previously mentioned study
19
 uses an analysis population of women aged 15-24, where this 
analysis uses women of all ages. Additionally, this study’s use of self-reported HIV status, as 
opposed to laboratory-confirmed status, may account for differing results.   
 This analysis’ strengths include use of a large, representative study population and the 
use of self-reported HIV status. To my knowledge, no studies have used self-reported HIV status 
from the 2010 MDHS to describe contraceptive method use. This analysis’ use of self-reported 
HIV status offers a unique glance at the methods of contraception used by a woman and what she 
believes her HIV status to be, which may be different that her laboratory-confirmed status. The 
use of self-reported HIV status allows us to estimate the health behavior implications of 
perceived HIV status. While we cannot confirm a temporal relationship, it is possible that a 
woman’s perceived HIV status may be influencing the current method of contraception she is 
using. While the unique use of this data is a strength of this analysis, it is also a limitation. 
Comparisons of laboratory-confirmed HIV status and self-reported status from the 2010 MDHS 
have shown that the true number of HIV-positive women in the population may be 
underestimated by self-reports.
21
 Self-reported HIV-positive responses may underestimate 
laboratory-confirmed HIV-positive results for a number of reasons: 1) the respondent was given 
a false negative result after her last HIV test; 2) the respondent has seroconverted since her last 
test, though she was HIV-negative at the time of the test; 3) the respondent misreported her HIV 
status on purpose. However, self-reported data is never entirely reliable, especially in this 
context, where respondents are asked to disclose personal information to an interviewer. 
 The present study highlights the need for contraceptive-based interventions to prevent 
MTCT. Overall LARC use is low in Malawi despite its proven effectiveness at preventing 
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unplanned pregnancies. While the WHO recommends interventions that utilize contraception to 
prevent MTCT, only a small number of PMTCT programs in sub-Saharan Africa specifically 
focus on preventing unplanned pregnancies in HIV-positive women. For HIV-positive women 
who desire future births, LARCs should be utilized as first-line contraceptive methods to prevent 
MTCT because they allow HIV-positive women to space births until they can access other 
PMTCT services such as ARV prophylaxis. LARCs are safe for most women,
11
 and acceptance 
is likely to be high among both clinicians and patients, given the proper education.
14
 To ensure 
the success of these future interventions, further research should attempt to determine the barriers 
preventing widespread LARC utilization in Malawi.  
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